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Short reports
A new simple enzyme assay for pre- and postnatal
diagnosis of infantile neuronal ceroid lipofuscinosis
(INCL) and its variants
Y V Voznyi, J L M Keulemans, G M S Mancini, C E Catsman-Berrevoets, E Young,
B Winchester, W J Kleijer, O P van Diggelen
Abstract
Palmitoyl-protein thioesterase (PPT) de-
ficiency was recently shown to be the pri-
mary defect in infantile neuronal ceroid
lipofuscinosis (INCL). The available en-
zyme assay is complicated and impracti-
cal for diagnostic use and is, in practice,
unavailable. We have developed a new
fluorimetric assay for PPT based on the
sensitive fluorochrome 4-methylumbelli-
ferone. This PPT assay is simple, sensi-
tive, and robust and will facilitate the
definition of the full clinical spectrum
associated with a deficiency of PPT. PPT
activity was readily detectable in fibro-
blasts, leucocytes, lymphoblasts, amniotic
fluid cells, and chorionic villi, but was
profoundly deficient in these tissues from
INCL patients. Similarly, a deficiency of
PPT was shown in patients with the
variant juvenile NCL with GROD. These
results show that rapid pre- and postnatal
diagnosis can be performed with this new
enzyme assay for PPT.
(J Med Genet 1999;36:471–474)
Keywords: infantile neuronal ceroid lipofuscinosis;
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The neuronal ceroid lipofuscinoses (NCL) are
a group of inherited, progressive encephalopa-
thies characterised by lipofuscin-like inclusions
in various tissues. At least four distinct clinical
forms have been described. The infantile form
of neuronal ceroid lipofuscinosis (INCL,
Santavuori-Haltia disease, MIM 256730) is an
early onset, neurodegenerative disease charac-
terised by psychomotor regression, seizures,
and progressive macular degeneration leading
to blindness after the first year. Severe brain
atrophy is observed by neuroimaging. The
inheritance of INCL is autosomal recessive and
the classical form is frequent in Finland (1 in
13 000 births) and rare in the rest of the world.
Electron microscopical investigations of skin or
rectal biopsies show the characteristic granular
osmiophilic deposits (GROD).
Until recently, the confirmation and classifi-
cation of the subtypes was based entirely on the
appearance of the pathological inclusion bod-
ies, being GROD, fingerprint-, or curvilinear
structures.1 During the last few years rapid
advances have been made in discovering the
primary defects in various forms of NCL. In
1995 the gene involved in juvenile NCL
(CLN3) was identified by the Batten disease
consortium.2 The corresponding protein is an
integral lysosomal membrane protein,3 but its
biological role is still unknown. In 1997, Sleat
et al4 showed that patients with the classical
form of late infantile NCL had mutations in a
gene (CLN2) which had homology to bacterial
pepstatin insensitive carboxypeptidases. A cor-
responding carboxypeptidase was found to be
deficient in brain extracts from late infantile
NCL patients.
In 1995, Vesa et al5 reported a deficiency of
palmitoyl-protein thioesterase (PPT) in pa-
tients with the infantile form of NCL and
found mutations in the corresponding CLN1
gene. PPT is a typical soluble lysosomal hydro-
lase which is routed to lysosomes through the
mannose-6-phosphate signal.6 This classifies
INCL as a genuine lysosomal storage disorder
and has ended the debate about whether infan-
tile NCL belongs to the group of lysosomal
storage disorders.
The published enzyme assay for PPT7 uses a
[3H]-S-palmitoyl-H-Ras protein as substrate.
The substrate has been made in a baculovirus
expression system labelled in situ with [3H]-
palmitate followed by elaborate purification.
PPT hydrolyses the thioester linkage between
the palmitoyl group and the sulphur atom of
particular cysteine residues from the H-Ras
protein. Unfortunately, this sophisticated assay
is not practical for the diagnostic enzyme labo-
ratory. Recently, a modification of this assay
using a [3H]-S-palmitoyl-peptide has been
published.8 We present here a novel and simple
assay for PPT based on the widely used fluoro-
chrome 4-methylumbelliferone, show its appli-
cation in rapid postnatal enzyme analysis, and
report the first, retrospective, prenatal enzyme
analyses of cases aVected with INCL.
Patients and methods
Fibroblasts and leucocytes were obtained from
patients with the typical clinical signs and
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symptoms of INCL. The diagnosis was con-
firmed by the finding of GROD in appropriate
tissues.
The synthetic substrate for palmitoyl-protein
thioesterase (PPT) was prepared by linking
4-methylumbelliferyl-6-thio-â-D-galactopyrano-
side (MU-6-thio-â-galactoside) to palmitate
through a thioester bond (MU-6S-Palm-âGal;
available from Moscerdam Substrates, for in-
quiries O P van Diggelen). Total leucocytes were
isolated from heparinised blood as described
previously9 and frozen until use. Skin fibroblasts
were cultured according to routine procedures
in Ham’s F10 medium supplemented with 10%
fetal bovine serum and antibiotics. The cells
were harvested with trypsin seven days after the
last subculture and stored at −70°C until use.
Lymphoblasts were prepared by transforming
peripheral blood lymphocytes with Epstein Barr
virus, according to standard procedures. Ho-
mogenates were prepared by sonication of cell
material in water. For the standard one step PPT
assay, reaction mixtures consisted of 10 µl
homogenate (2 µg protein for fibroblasts,
lymphoblasts, and amniocytes; 5 µg for chori-
onic villi and leucocytes) and 20 µl substrate
solution containing 0.64 mmol/l MU-6S-Palm-
âGal, 15 mmol/l dithiothreitol (DTT), 0.375 %
(w/v) Triton X-100, and 0.1 U â-galactosidase
from Aspergillus oryzae (Sigma) in McIlvain’s
phosphate/citrate buVer, pH 4.0. The reaction
mixtures were incubated for 17 hours at 37°C.
The exogenous â-galactosidase from Aspergillus
was necessary since the endogenous
â-galactosidase activity was insuYcient to con-
vert the reaction intermediate MU-6-thio-â-
galactoside quantitatively. PPT activities were
similar in acetate buVer and phosphate/citrate
buVer. Mg2+ and EDTA (7 mmol/l) had no effect
on the PPT activity.
In the two step assay, the first incubation was
identical to the standard assay, except that
Aspergillus â-galactosidase was not added. After
the first incubation of 17 hours at 37°C, the
samples were boiled for two minutes to stop the
PPT reaction. After cooling, 0.1 U of Aspergil-
lus â-galactosidase was added and the second
step was incubated for six hours at 37°C to
hydrolyse the reaction intermediate MU-6-
thio-â-galactoside. In the experiment to deter-
mine the optimum pH, buVer was added to
adjust the pH to 4.5. Finally, all enzymatic
reactions were terminated by the addition of
200 µl of 0.5 mol/l Na2CO3/NaHCO3, pH 10.7
and the fluorescence of 4-methylumbelliferone
(MU) was measured in a FluoroCount (Pack-
ard) fluorimeter. Protein was determined as
described previously.9
Results
The potential of 4-methylumbelliferyl-6-
thiopalmitoyl-â-D-galactopyranoside (MU-
6S-Palm-âGal) as an artificial substrate for the
palmitoyl-protein thioesterase (PPT) was in-
vestigated. The liberation of MU from MU-6S-
Palm-âGal cannot be accomplished by the sole
action of PPT, since this enzyme only hydro-
lyses the palmitoyl thioester linkage, yielding
the non-fluorescent reaction intermediate
MU-6-thio-â-galactoside. The endogenous
â-galactosidase, present in cell homogenates,
was not able to hydrolyse the reaction interme-
diate quantitatively, but exogenous
â-galactosidase from Aspergillus (0.1 U) could
hydrolyse MU-6-thio-â-galactoside completely
within six hours, albeit at a low rate (data not
shown). The release of MU required the pres-
ence of a reducing agent (DTT) to prevent for-
mation of disulphides between MU-6-thio-â-
galactosides. Using the two step assay (see
Patients and methods section), the optimum
pH of PPT for leucocytes and fibroblasts was
shown to be 4 (fig 1A). Activities at pH >6
could not be determined owing to spontaneous
hydrolysis of the palmitoyl thioester bond of
MU-6S-Palm-â-Gal. The pH optima for am-
niocytes and chorionic villi were similar (not
illustrated). In fibroblasts and leucocytes from
INCL patients, the thioesterase activity at pH
3.5 was almost absent but gradually increased
at higher pH values, reaching control levels at
pH 6. This indicated that thioesterases other
than PPT can also hydrolyse the substrate at
higher pHs. All further experiments were done
at pH 4. The PPT assay could also be carried
out in one step by adding exogenous
â-galactosidase together with the substrate. In
fig 1B, PPT activities in fibroblasts and leuco-
cytes, measured in one and two steps, are com-
pared. In the two step assay, diVerent incuba-
tion times for the first (PPT) step were
followed by an incubation period of six hours
with exogenous â-galactosidase. In the one step
assay, activities are underestimated if incuba-
Figure 1 (A) pH dependence of palmitoyl-protein thioesterase activity. Fibroblasts from a control (open triangles) and an INCL patient (filled triangles);
leucocytes from a control (open squares) and an INCL patient (filled squares). (B) Time course of palmitoyl-protein thioesterase activity in the one step
assay (closed symbols) and two step assay (open symbols). Control fibroblasts (triangles) and control leucocytes (squares). (C) Protein dependence of
palmitoyl-protein thioesterase activity. Control fibroblasts (triangles), control leucocytes (squares), control amniocytes (diamonds), control chorionic villi
(circles). Reaction conditions as described in the Patients and methods section, except for the parameter which is varied.
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tion times are less than four hours owing to the
slow hydrolysis of the reaction intermediate
MU-6-thio-â-galactoside by â-galactosidase.
However, after an overnight incubation, the
one step assay approached the “true” PPT
activity as measured in the two step assay.
Therefore, a one step assay with a 17 hour
incubation was used in the experiments
described below. Amniocytes and chorionic
villi gave similar results (not shown). The PPT
activity increased in a non-linear manner with
the amount of protein up to 8 µg (fig 1C). As a
compromise between linearity and sensitivity
of the assay, we chose the fixed protein
amounts as mentioned in the Patients and
methods section. The apparent Km was
estimated to be 0.2 mmol/l for fibroblasts and
leucocytes (data not shown).
Under standard conditions PPT activity was
readily detectable in control leucocytes, lym-
phoblasts, fibroblasts, amniocytes, and chori-
onic villi (table 1), whereas the activity was
reduced in leucocytes and fibroblasts from
obligate heterozygotes for INCL. PPT activity
was profoundly deficient in fibroblasts, total
leucocytes, and lymphoblasts from patients
with INCL (table 1). PPT activity was also
deficient in leucocytes from the variant juvenile
NCL with GROD. In fibroblasts from patients
with I cell disease, a multiple lysosomal enzyme
deficiency, PPT was considerably reduced.
Retrospectively, a clear deficiency of PPT
was shown in amniotic fluid cells (amniocytes)
and chorionic villi from fetuses aVected with
INCL (table 1). This shows the feasibility of
prenatal enzyme analysis for INCL.
Discussion
We have synthesised an artificial substrate for
palmitoyl-protein thioesterase with a thioester
bond between palmitate and 6-thiogalactose
linked to the fluorochrome 4-methylumbelli-
ferone (MU-6S-Palm-âGal). The specificity of
this substrate was shown by the deficiency of
PPT in various cell types from patients with the
infantile form of neuronal ceroid lipofuscinosis
and its variants. To our knowledge, thioesters
between fatty acids and thio-sugars do not exist
in nature and our results show that PPT does
not discriminate between the compounds to
which the fatty acid thioester is linked. This is
consistent with the observation that PPT also
hydrolyses palmitoyl-CoA.7 Thus, PPT shares
a property typical of most lysosomal enzymes,
viz that it is the terminal group of the linkage
hydrolysed by the enzyme that determines the
specificity of the enzyme. This property has
been exploited for diagnostic purposes and
nearly all the lysosomal storage disorders are
now diagnosed by enzyme assays using artifi-
cial substrates based on the sensitive fluoro-
chrome 4-methylumbelliferone.
Since the primary defect in infantile NCL
was reported,5 it has become clear that classifi-
cation based on age of onset and electron
microscopical histopathology is no longer
completely reliable and that a heterogeneous
clinical phenotype of a deficiency of PPT is
emerging. Das et al10 showed that only half of
the patients with PPT deficiency in the USA
and Canada have the severe phenotype charac-
teristic of the Finnish INCL. The availability of
a simple enzyme assay will greatly facilitate the
definition of the full clinical spectrum of a defi-
ciency of PPT and it is an intriguing thought
that late onset patients with PPT deficiency,
with or without GROD, might be discovered by
enzyme analysis. The correlation between the
presence of GROD and a deficiency of PPT is
good but not absolute. A patient with GROD
in ganglion cells, but homozygous for a
mutation in the gene for classical juvenile NCL
(CLN3) has been reported.11
In the Finnish population, screening for just
a single mutation has been an eYcient means
of confirming the diagnosis in 95% of the
INCL patients,5 albeit that the sensitivity is not
100%. In non-Finnish patients with a PPT
deficiency, a large number of diVerent muta-
tions has been found,10 indicating that screen-
ing for known mutations is not eYcient in
identifying the NCL subtype. In contrast, the
present assay of functional PPT screens for all
known and unknown mutations leading to a
PPT deficiency. Therefore, enzyme analysis
should always precede mutation analysis in the
process of establishing the diagnosis in new
patients. In fact, enzymatic confirmation of
PPT deficiency in Dutch patients suspected of
having INCL has initiated a screening pro-
gramme for mutations in the CLN1 gene in
The Netherlands.
Our fluorogenic PPT assay is much more
convenient than the assays using purified
[3H]-palmitoylated-H-Ras protein7 or a [3H]-
palmitoylated peptide.8 We have shown that the
present PPT assay is a straightforward way to
confirm the diagnosis of patients suspected of
having INCL. We have also shown that it is
possible to see a deficiency of PPT in fetal
samples.
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